ImmunoGen

ImmunoGen, Inc. (NASDAQ: IMGN) is a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.[2]

ImmunoGen Inc.
TypePublic
NASDAQ: IMGN
Russell 2000 Component
IndustryBiopharmaceuticals
Founded1981
Headquarters
Waltham, Massachusetts
,
United States
Revenue $65.2 Million(2019)[1]
Number of employees
75
Websitewww.immunogen.com

An ImmunoGen ADC contains a manufactured antibody that binds to a target found on cancer cells, with one of the company's potent cell-killing agents attached as a "payload". The antibody serves to deliver the cell-killing agent specifically to cancer cells bearing its target and the payload serves to kill these cells. In some cases, the antibody also has anticancer activity.

Linkage technology

Currently approved ADCs with ImmunoGen technology employ one of the company's maytansinoid cell-killing agents, either DM1 or DM4, or one of the company's DNA-acting IGN payloads.

ImmunoGen also developed isatuximab, a monoclonal antibody without linkage to a toxin.

Pipeline

ImmunoGen uses its ADC technology to develop its own product candidates. Products currently in clinical-stage development include:[5]

Collaborations & licensing

The company also selectively outlicenses limited use of its technology to other companies. Companies licensing ImmunoGen's technology include Amgen, Bayer HealthCare, Biotest, Genentech/Roche, Eli Lilly, Novartis, Sanofi, and Takeda.[5] Roche's Kadcyla (ado-trastuzumab emtansine) utilizes ImmunoGen's ADC technology. It has been approved and launched in a number of countries, including the US, where it is marketed by Genentech, a member of the Roche Group.[9][10] In October 2015, the company disclosed that Kadcyla had failed to meet its primary endpoint in the Phase II/III GATSBY trial investigating the second line treatment of HER2-positive advanced gastric cancer.[11]

References
  1. https://investor.immunogen.com/news-releases/news-release-details/immunogen-reports-recent-progress-and-2019-financial-results
  2. "ImmunoGen Inc., Inc. stock price Yahoo Finance". Finance.yahoo.com. Retrieved 2014-03-09.
  3. AG, MorphoSys (26 January 2016). "MorphoSys Announces Clinical Milestone for Start of Bayer's Phase 2 Trial Designed to Support Registration of Anetumab Ravtansine". GlobeNewswire News Room.
  4. Dombret, Hervé; Hatteville, Laurence; Oprea, Corina; Bories, Pierre; O'Brien, Susan; Jabbour, Elias; Cortes, Jorge; Thomas, Xavier G.; Escoffre-Barbe, Martine; Marolleau, Jean-Pierre; Kelly, Kevin; Leguay, Thibaut; Atallah, Ehab; Kim, Stella K.; Lioure, Bruno; Kantarjian, Hagop M. (1 March 2016). "A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia". Clinical Lymphoma, Myeloma and Leukemia. 16 (3): 139–145. doi:10.1016/j.clml.2015.12.004. PMC 5557033 – via www.clinical-lymphoma-myeloma-leukemia.com.
  5. "Target a Better Now - ImmunoGen for ADC Technology-focused Cancer Treatment". ImmunoGen.
  6. "Meeting Library - Meeting Library". meetinglibrary.asco.org.
  7. "ImmunoGen, Inc. Announces Data Presentations at Upcoming 57th ASH Annual Meeting and Exposition". www.businesswire.com. 1 December 2015.
  8. "A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors - Full Text View - ClinicalTrials.gov". clinicaltrials.gov.
  9. "Genentech". www.gene.com.
  10. "KADCYLA® for certain types of HER2+ Breast Cancer". www.kadcyla.com.
  11. "Archived copy". Archived from the original on 2015-10-24. Retrieved 2015-10-24.CS1 maint: archived copy as title (link)


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.